(PRESS RELEASE) HONG KONG and NEW YORK, — The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions. By leveraging SCOPE’s knowledge and expertise in eye drop product formulation science, together with CEVR’s extensive experience in ocular drug discovery and delivery translational research, the pair are committed to developing innovative product approaches for doctor and patient unmet ocular surface disease needs.
Professor Ben Thompson, CEO and scientific director of CEVR, remarked, “We are thrilled to collaborate with SCOPE Health Inc., a leading innovator in management solutions for ocular surface diseases. Through this collaboration and SCOPE’s ardent support, engagement in areas such as dry eye management at the practice level and global outreach will increase substantially to deliver tangible change. The research results will advance CEVR’s mission to develop technologies that preserve and enhance vision worldwide. This partnership merges cutting-edge science with formulation and commercialization expertise, paving the way for a transformative solution to support developing technologies that preserve and enhance healthy vision worldwide.”
Tom Freyne, CEO of SCOPE Health Inc., said, “Disrupting the status quo and establishing a new standard of care for ocular surface diseases requires collective efforts. Under the leadership of CEVR’s Principal Investigators, Prof. Lyndon Jones, and Dr. Chau-Minh Phan, along with Dr. Howard Ketelson, head of Ideation & Discovery at SCOPE, this collaboration collectively harnesses our expertise’s to develop and commercialize differentiated and clinically valued eyecare products.”
